Cell-free DNA Testing Market – Global Drivers, Restraints, Opportunities, Trends, and Forecasts: 2017–2023 Overview: Cell-free DNA (cfDNA) are non-encapsulated fragments of DNA molecule present in blood and urine that has huge screening and diagnostic applications. CfDNA is used for fetal DNA screening tests to detect chromosomal abnormalities, as a biomarker for specific mutations detection i

Published by Infoholic Research on 22nd November 2017 | Ref: 842450 | This Report Is In Stock

$2500 | Single User
$2750 | Site License
$3000 | Enterprise License
$2500 | Single User
$2750 | Site License
$3000 | Enterprise License

Introduction

Cell-free DNA Testing Market – Global Drivers, Restraints, Opportunities, Trends, and Forecasts: 2017–2023

Overview: Cell-free DNA (cfDNA) are non-encapsulated fragments of DNA molecule present in blood and urine that has huge screening and diagnostic applications. CfDNA is used for fetal DNA screening tests to detect chromosomal abnormalities, as a biomarker for specific mutations detection in cancer patients, as a biomarker to detect post transplantation rejection, and other applications. According to the Center of Disease Control and Prevention, around 6,000 babies are born with Down syndrome every year that is nearly 1 in every 700 babies and the disease incidence is increased by about 30% between 1979 and 2003. Further, according to the study by World Health Organization, approximately 14 million new cancer cases were diagnosed and is expected to grow by about 70% over the next 2 decades.

The cfDNA testing market is booming due to advanced maternal age, increasing number of chronic diseases, change in lifestyle that leads to lifestyle diseases like cancer, and unhealthy food habits. The rising disease incidence along with the increasing medical spending and healthcare expenditure provide opportunities for molecular diagnostics company to come up with more number of innovative tests in the market. However, there is a huge market space for molecular diagnostic companies to come up with novel tests directing on transplantation rejection cases like liver, lung, etc, in the near future.

Market Analysis: The “Global Cell-free DNA Testing Market” is estimated to witness a CAGR of 26.5% during the forecast period 2017–2023. The market is analyzed based on three segments, namely test types, application, and regions.

Regional Analysis: The regions covered in the report are North America, Europe, Asia Pacific, and Rest of the World (RoW). The Americas is set to be the leading region for the cfDNA testing market growth followed by Europe. Asia Pacific and RoW are set to be the emerging regions.

Test Types Analysis: The global cfDNA testing market by test type is segmented into cell-free fetal DNA tests (also called NIPT), circulating tumor DNA tests, and donor-derived cell-free DNA tests. Cell-free fetal DNA tests is the largest segment, as women are more career-oriented, and the trend is seen in western countries to start family at a late age. These lead to an increase in the average maternal age. Donor-derived cfDNA tests are the fastest growing segment. The rising number of organ donors, increasing transplantation procedures, increasing healthcare awareness have made them the fastest growing segment of the market. The market is also witnessing various acquisitions, agreements, and new product launches and collaborations among the top players, which is defining the future of the global cfDNA testing market.

Application Analysis: The global cfDNA testing market by application is segmented into Gynecology, Oncology, and Transplantation. Gynecology occupies the largest market share and transplantation is expected to be the fastest growing segment during the forecasted period.

Key Players: Natera, Inc., Beijing Genomics Institute, F. Hoffmann-La Roche (Roche), Laboratory Corporation of America Holdings, Illumina, Inc., Guardant Health, Trovagene, Inc., Biocept, Inc., and other predominate & niche players.

Competitive Analysis: Currently, the cfDNA tests dominate the global cfDNA testing market. A lot of new players are focusing on this market to provide innovative tests with high accuracy and less turnaround time. Many major players in the market are launching new products to maintain their leadership in the market. Apart from this, the big players are acquiring small companies in the market to enhance their product portfolio and maintain their market leadership. For instance, in September 2016, LabCorp acquired Sequenom to strengthen its non-invasive prenatal testing product portfolio.

Benefits: The report provides complete details about the usage and adoption rate of cfDNA tests in various applications and regions. With that, the key stakeholders can know about the major trends, drivers, investments, vertical player’s initiatives, government initiatives toward the test adoption in the upcoming years along with the details of commercial tests available in the market. Moreover, the report provides details about the major challenges that are going to impact the market growth. Additionally, the report gives complete details about the key business opportunities to key stakeholders to expand their business and capture the revenue in the specific verticals to analyze before investing or expanding the business in this market.

Key Stakeholders:

Table of Contents

Table of Contents

1 INDUSTRY OUTLOOK 9

1.1 Industry overview 9

1.2 Total addressable market 9

1.3 Industry Trends 10

2 Report Outline 11

2.1 Report Scope 11

2.2 Report Summary 11

2.3 Research Methodology 12

2.4 Report Assumptions 12

3 Market Snapshot 13

3.1 Market Definition – Infoholic Research 13

3.2 Importance of Cell-Free DNA testing 13

3.3 Complications of Cell-Free DNA testing 13

3.4 Segmented Addressable Market (SAM) 14

3.5 Industry Trends 14

3.6 Related Markets 16

4 Market Outlook 16

4.1 Overview 16

4.2 Regulatory framework 17

4.3 Funding scenario 18

4.4 Market segmentation 19

4.5 PEST Analysis 20

4.6 Porter 5(Five) Forces 21

5 Market Characteristics 22

5.1 DRO – Global Cell-free DNA testing Market Dynamics 22

6 Test Types: Market Size and Analysis 28

6.1 Overview 28

6.2 Non-invasive prenatal testing (NIPT) 29

6.3 Circulating tumour DNA tests 30

6.4 Donor-derived cell free DNA tests 32

7 Application: Market Size and Analysis 33

7.1 Overview 33

7.2 Prenatal testing 35

7.3 Cancer 35

7.4 Transplantation diagnostics 36

8 Regions: Market Size and Analysis 37

8.1 Overview 37

8.2 North America 38

8.3 Europe 39

8.4 APAC 42

8.5 Rest of the World 43

9 Competitive Landscape 45

9.1 Overview 45

10 Vendor Profiles 48

10.1 Natera, Inc. 48

10.2 Laboratory Corporation of America Holdings (LABCORP) 54

10.3 Illumina, Inc., 61

10.4 BEIJING GENOMICS INSTITUTE 68

10.5 F.Hoffmann-La Roche Ltd 71

Companies to Watch For 78

10.6 CareDx, Inc 78

10.7 LifeCodexx AG 80

10.8 Biocept, Inc. 81

10.9 Quest Diagnostics 84

10.10 Guardant Health 87

10.11 Inivata Limited 89

10.12 Personal Genome Diagnostics 90

10.13 Trovagene 91

Annexure 94

Abbreviations 94

Additional Details

Publisher

Infoholic Research

Publisher Information

Reference

842450 |

Number of Pages

96

Report Format

PDF

This report is published by Infoholic Research

Download Free Report Summary PDF

Cell-free DNA Testing Market – Global Drivers, Restraints, Opportunities, Trends, and Forecasts: 2017–2023
Overview: Cell-free DNA (cfDNA) are non-encapsulated fragments of DNA molecule present in blood and urine that has huge screening and diagnostic applications. CfDNA is used for fetal DNA screening tests to detect chromosomal abnormalities, as a biomarker for specific mutations detection i [Updated: 22-11-2017] | Download PDF Summary

Download our FREE report summary PDF. It contains all the information on these web pages, plus a Proforma Invoice request form, should you need it to satisfy your company's internal order procedures.

Ordering Information

Orders are processed immediately and you will be notified of the despatch date on confirmation of your order.

Accepted Card Types

Payment

Buy now using our secure payment system.